DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) saw a large growth in short interest in February. As of February 15th, there was short interest totalling 232,300 shares, a growth of 21.1% from the January 31st total of 191,900 shares. Based on an average daily volume of 113,800 shares, the short-interest ratio is currently 2.0 days.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.

DiaMedica Therapeutics Trading Down 3.0 %

Shares of DMAC stock opened at $5.77 on Friday. The firm has a 50-day moving average price of $5.92 and a 200 day moving average price of $4.99. DiaMedica Therapeutics has a twelve month low of $2.14 and a twelve month high of $6.82. The company has a market capitalization of $246.73 million, a price-to-earnings ratio of -10.30 and a beta of 1.52.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DMAC. Point72 Asia Singapore Pte. Ltd. acquired a new position in DiaMedica Therapeutics in the 3rd quarter valued at about $40,000. Balyasny Asset Management L.P. acquired a new position in shares of DiaMedica Therapeutics during the 4th quarter valued at about $79,000. Y Intercept Hong Kong Ltd acquired a new position in shares of DiaMedica Therapeutics during the 4th quarter valued at about $81,000. Raymond James Financial Inc. acquired a new position in shares of DiaMedica Therapeutics during the 4th quarter valued at about $83,000. Finally, Bank of Montreal Can acquired a new position in shares of DiaMedica Therapeutics during the 4th quarter valued at about $84,000. Institutional investors and hedge funds own 10.12% of the company’s stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.